Retention rate of a novel autoinjector e-Device introduced to patients with chronic arthritis treated with certolizumab pegol in clinical practice: an observational implementation study
Authors' conclusion
An initial large dropout was evident within the first 8 weeks, with almost no dropouts thereafter. The reasons for withdrawal were primarily patient requests.
Study context
- Population
- Adults (18–85 years) with RA, axSpA or PsA treated with certolizumab pegol (CZP), recruited from rheumatology clinics at initiation of, or switching to, the e-DeviceNetherlands 25, Denmark 15, Sweden 19
- Participants
- 59 adults
- Outcome
- Clinical retention rate of the e-Device
Methodological detailsmultinational (Netherlands, Denmark, Sweden), descriptive statistics, Patients administered three consecutive self-injections at home, 6 patients (10%) started CZP de novo; the rest switched device
- Multinational (Netherlands, Denmark, Sweden)
- Descriptive statistics
- Patients administered three consecutive self-injections at home
- 6 patients (10%) started CZP de novo; the rest switched device
Main finding
As reported in the abstract
Overall retention rate
Retention rate after 52 weeks
42%
Retention rate after 104 weeks
38%
Sharp decline at week 8
34%
Withdrawals between weeks 32 and 112
4
6.8%
Observational data: associations, not effects.
Further findings
Reasons for withdrawal
- Primary reason for withdrawal was the patient's request
Stratification by country
- Significant differences for some outcomes
Original publication
Retention rate of a novel autoinjector e-Device introduced to patients with chronic arthritis treated with certolizumab pegol in clinical practice: an observational implementation study. Scand J Rheumatol. Published 8 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →